Allergy Therapeutics (AGY)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

7.85p
   
  • Change Today:
    -0.15p
  • 52 Week High: 8.75p
  • 52 Week Low: 3.88p
  • Currency: UK Pounds
  • Shares Issued: 4,766.44m
  • Volume: 135,995
  • Market Cap: £374.17m
  • RiskGrade: 268

Allergy Therapeutics eyes 2020 start for hay fever inoculation trials

By Iain Gilbert

Date: Thursday 25 Apr 2019

LONDON (ShareCast) - (Sharecast News) - Commercial biotechnology company Allergy Therapeutics will kick off phase III trials of its short-course inoculation for grass pollen-induced hay fever in the second half of 2020 following a successful round of meetings with German and American regulatory bodies.
Allergy told investors on Thursday that insights gained from recent clinical work will also be incorporated into its latest batch of tests, which will be overseen by both the US Food and Drug Administration and Garmany's Paul Ehrlich Institut.

Chief executive Manuel Llobet said: "This product has the potential to become a much-needed treatment option for the estimated 25-30% of the EU and US populations who are allergic to grass pollen1, and we believe that the PQ Grass trial will enable us to demonstrate the efficacy of this short-course grass pollen immunotherapy."

Elsewhere, a readout from Allergy's recent phase I clinical assessment of its Acarovac dust mite allergy drug was set to arrive later in the quarter, while a manufacturing scale-up of its Polyvac peanut product was also said to be progressing well ahead of a first-in-human study.

As of 1000 BST, Allergy shares had picked up 1.55% to 9.80p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AGY Market Data

Currency UK Pounds
Share Price 7.85p
Change Today -0.15p
% Change -1.88 %
52 Week High 8.75p
52 Week Low 3.88p
Volume 135,995
Shares Issued 4,766.44m
Market Cap £374.17m
RiskGrade 268

AGY Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
68.95% below the market average68.95% below the market average68.95% below the market average68.95% below the market average68.95% below the market average
65.85% below the sector average65.85% below the sector average65.85% below the sector average65.85% below the sector average65.85% below the sector average
Price Trend
93.47% above the market average93.47% above the market average93.47% above the market average93.47% above the market average93.47% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Income Not Available
Growth
53.41% below the market average53.41% below the market average53.41% below the market average53.41% below the market average53.41% below the market average
79.31% below the sector average79.31% below the sector average79.31% below the sector average79.31% below the sector average79.31% below the sector average

AGY Dividends

No dividends found

Trades for 29-Aug-2025

Time Volume / Share Price
16:35 12,905 @ 7.85p
16:35 6,411 @ 7.85p
16:35 6,494 @ 7.85p
15:56 8,024 @ 7.88p
11:43 20,000 @ 8.18p

AGY Key Personnel

CEO Manuel Llobet

Top of Page